GlassScriptPhysician profile
Lawrence R Strawbridge
NPI 1467405324
$298.65
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $45.79.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $54.19 | 2019 | |
| Janssen Biotech, INC. | $51.66 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $48.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.99 | 2019-2020 | |
| Boston Scientific Corporation | $20.09 | 2019 | |
| Astellas Pharma US INC | $17.94 | 2019 | |
| Seagen INC. | $16.39 | 2019 | |
| Pfizer INC. | $14.15 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.10 | 2019 | |
| Allergan, INC. | $12.55 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $11.93 | 2020 | |
| Travere Therapeutics, INC. | $3.82 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Strawbridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.